Drugs / prinomastat
prinomastat
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00004200 | Oct 1999 → Jan 2002 | central nervous system neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00004199 | Mar 1999 → Jul 2001 | lung cancer | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00003343 | Mar 1998 → Jan 2001 | prostate cancer | Pfizer | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prinomastat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004200 ↗ |
| Known as | AG3340 | “A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor Prinomastat (AG3340) in Combination With Gemcitabine and Cisplatin in...” NCT00004199 ↗1“treated with prinomastat (AG3340) or placebo and temozolomide following radiotherapy.” NCT00004200 ↗ |
| Known as | KB-R-9896 | ChEMBL registry synonym — accepted as the source's own label CHEMBL75094 ↗ |
| Action | Inhibit | “Matrix Metalloprotease Inhibitor Prinomastat” NCT00004199 ↗ |
| Modality | Small molecule | — CHEMBL75094 ↗ |
| Route | Oral | “Patients receive oral prinomastat or placebo twice daily” NCT00004199 ↗ |